NSAIDs can raise BP and blunt ACEi/ARB/diuretic effects. For exams, calcium channel blockers are least affected and remain effective.
When patients require NSAIDs, calcium channel blockers are the antihypertensive class whose BP-lowering effect is least blunted.
A 66-year-old white woman with a longstanding history of rheumatoid arthritis presents to you for a routine visit. On a visit 3 months ago, her blood pressure was 145/90 mm Hg and you recommended lifestyle changes. Today, her blood pressure is 150/86 mm Hg and you diagnose her with hypertension.
She also complains of pain, so she is taking acetaminophen and ibuprofen to manage her pain in addition to monthly injections of anti-tumor necrosis factor α agents, which are managed by her rheumatologist.
Which class of antihypertensive agents is most effective in patients receiving non-steroidal anti-inflammatory drugs?
Answer Options:
Examinees often miss this because they overgeneralize “first-line HTN therapy” (ACEi/ARB/thiazide/CCB) without accounting for drug-induced hypertension and pharmacodynamic antagonism. NSAIDs (e.g., ibuprofen at anti-inflammatory doses) can raise BP and commonly blunt the antihypertensive effect of agents dependent on renal prostaglandin–mediated vasodilation and natriuresis—most notably RAAS blockers and diuretics.
For board purposes, the most testable takeaway is that calcium channel blockers—especially dihydropyridines—maintain BP-lowering efficacy better than other classes during NSAID use. This aligns with contemporary hypertension guidance that flags NSAIDs as contributors to poor BP control (ACC/AHA 2017; AHA resistant hypertension statement 2018) and with the long-standing clinical pharmacology consensus used in exam item banks.
| Option | What It Tests / Implies | Why It’s Wrong Here |
|---|---|---|
| beta-blockers | Recognition of alternative first-line agents/compelling indications | NSAIDs can still worsen BP control; beta-blockers are not the classic “least affected” class in NSAID users and are not first-line absent a compelling indication. |
| angiotensin-converting enzyme inhibitors | Standard first-line HTN therapy | NSAIDs can blunt ACEi effects via reduced renal prostaglandins and altered renal hemodynamics (and can worsen kidney function risk in combination settings). |
| angiotensin receptor blockers | Same as ACEi but with different tolerability | Similar NSAID-related attenuation of BP lowering as ACE inhibitors. |
| calcium channel blockers | Drug interaction recognition | Correct: CCB BP-lowering is least affected by NSAIDs and is the most exam-reliable choice in this scenario. |
In a patient who must take NSAIDs, pick a calcium channel blocker when asked which antihypertensive is least blunted by NSAID therapy.
The stem tempts you to focus on “new HTN in an older adult” or RA comorbidities, but the hidden hinge is the medication list: ibuprofen. Boards love asking which antihypertensive “still works” when NSAIDs are on board—this is a pharmacology/renal physiology question disguised as routine primary care.
A 58-year-old man with HTN controlled on lisinopril develops knee OA and starts daily ibuprofen. Two weeks later, BP increases from 128/78 to 148/92. Best explanation?
A 70-year-old woman requires chronic naproxen for inflammatory arthritis. Which antihypertensive class is least affected by NSAIDs?
A patient with CKD stage 3 is on losartan and hydrochlorothiazide. He starts high-dose ibuprofen for back pain. What complication is he now at increased risk for?
A 62-year-old man with HTN and chronic inflammatory pain cannot stop NSAIDs. No CAD, HF, or CKD. Best initial antihypertensive to avoid loss of efficacy?
A 55-year-old woman’s BP becomes difficult to control after starting a new medication for musculoskeletal pain. Which medication is most likely responsible?
How would your antihypertensive choice and monitoring plan change if this same patient also had CKD stage 3 and was already taking an ACE inhibitor plus a thiazide when she started daily NSAIDs?
Q1: Why do NSAIDs raise blood pressure?
A: The ABIM expects recognition that renal COX inhibition lowers vasodilatory prostaglandins, promoting sodium retention and increased systemic vascular resistance.
Q2: Which antihypertensive class is least affected by NSAIDs on exams?
A: Calcium channel blockers (especially dihydropyridines) are the classic “least blunted” choice.
Q3: Why are ACE inhibitors/ARBs less effective with NSAIDs?
A: Boards test the concept that NSAIDs counteract renal hemodynamic and natriuretic pathways that support RAAS-blocker BP lowering.
Q4: What’s the kidney danger combination with NSAIDs?
A: The high-yield triad is NSAID + ACEi/ARB + diuretic (“triple whammy”) increasing AKI risk—commonly tested alongside BP control issues.
This question appears in Med-Challenger Internal Medicine Review with CME
Try for free and save. Ace your exams and meet your CME/MOC requirements for just $35 a month!
No matter your program, no matter the size, Med-Challenger for Groups and Institutions can better prepare your program or group, fulfill industry requirements, and increase test scores.
For personal medical education that includes board's prep, MOC, and CME requirements, Med-Challenger has you covered in Family Medicine, Emergency Medicine, Internal Medicine, Pediatrics, Pediatric Emergency Medicine, OBGYN, Physician Assistants, and Nurse Practitioners.
Learn how to choose the right ABFM QBank with tips on blueprint alignment, realistic questions, strong explanations, and effective study tools.
In challenging case-based scenarios in medicine, accurate deduction is crucial for effective patient care. Here are some techniques to help.
Create an effective study plan for the PEM board exam with strategies for using the blueprint, prioritizing topics, and practicing questions.